Mizukami, Takuro
Izawa, Naoki
Nakajima, Takako Eguchi
Sunakawa, Yu http://orcid.org/0000-0002-0163-7543
Article History
First Online: 9 April 2019
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript.
: Takuro Mizukami has received consulting fees from Merck Serono and a speaker honorarium from Merck Serono and Takeda Pharmaceutical Co. Ltd. Takako Eguchi Nakajima has received research grants from Merck Serono, Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan, and Sanofi KK and a speaker honorarium from Merck Serono, Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Eli Lilly Japan. Yu Sunakawa has received consulting fees from Takeda Pharmaceutical Co. Ltd. and a speaker honorarium from Takeda Pharmaceutical Co. Ltd. and Merck Serono. Naoki Izawa declares that he has no conflicts of interest that might be relevant to the contents of this manuscript.